Danish pharmaceutical innovator Novo Nordisk headed to the High Court in Pretoria, South Africa, to secure an injunction aimed at halting the commercial sale of unapproved copies of semaglutide—the core active pharmaceutical ingredient (API) driving its blockbuster weight-loss and diabetes treatments, Wegovy and Ozempic. Novo Nordisk South Africa filed a formal application seeking to restrain local compounding pharmacy iDexis from manufacturing, advertising, distributing, and commercializing “unregistered and untested” weight-loss formulations containing a semaglutide base, pending the court’s definitive consideration of the matter.
The documented litigation frameworks, administrative regulatory boundaries, and grey market expansion vectors feature:
-
Judicial Arguments Expressed by Legal Representatives:
-
Novo Nordisk’s Position: The drugmaker noted that its urgent legal action stems directly from deep operational concerns relating to patient safety, product quality, and regulatory oversight. The baseline legal debate centers on whether the active compound leveraged by iDexis to achieve its therapeutic effect is identical or substantially similar to proprietary semaglutide, which legally mandates formal registration before it can be lawfully commercialized.
-
iDexis’s Defense: Senior Counsel Stefan Maritz, representing iDexis, rejected Novo Nordisk’s claims as entirely unsubstantiated, asking the court to compel the multi-national corporate entity to produce hard evidence supporting its allegations. He emphasized that iDexis’s compounding workflows strictly complied with localized statutory parameters, adding that there have been zero documented reports of adverse reactions from consumers utilizing their formulations. The presiding judge reserved judgment, stating an executive decision would be delivered as soon as possible.
-
-
Administrative Infractions and Quality Deficiencies Isolated by Regulators:
-
Under South African statutory frameworks, compounding—the highly specialized pharmaceutical practice of mixing or altering therapeutic drug ingredients tailored exclusively for individual patients—is tightly restricted. Large-scale manufacturing, batch formulation, or the mass marketing of unregistered medicines is completely prohibited.
-
Last month, a joint enforcement inspection conducted by the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) determined that iDexis was illicitly manufacturing GLP-1 receptor agonists, including tirzepatide, for broad commercial distribution exceeding regulatory thresholds. Citing serious technical deficiencies in quality control, biological safety, and compliance, authorities executed a seizure of physical assets and ordered an immediate recall of all components distributed to healthcare providers and independent pharmacies.
-
-
Surging GLP-1 Market Demand and the Proliferation of Grey Markets:
-
Macroeconomic demand for GLP-1 medications engineered for diabetes and weight management surged exponentially across South Africa last year following the local commercial rollouts of Eli Lilly’s blockbuster Mounjaro and subsequently Novo’s Wegovy.
-
Although the consumer cost for the lowest injected dose of Wegovy dropped from 3,090 rand ($183) to 1,873 rand, and the price of the maximum dose fell 27% to 3,746 rand, these price points remain financially prohibitive for a significant demographic of the population. Unable to afford authentic branded biologics, patients have systematically turned to cheaper compounded alternatives, inadvertently fueling a highly active grey market exploited by independent pharmacies and localized producers. Novo Nordisk’s litigation in Pretoria mirrors its aggressive anti-compounding enforcement campaigns within the United States jurisdiction targeting digital telehealth platforms and physical pharmacies that circumvent structural regulatory safeguards.
-